Advertisement

Preoperative Radiomic Approach to Evaluate Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma Patients Using Contrast-Enhanced Computed Tomography

  • Haotian Liao
  • Zhen Zhang
  • Jie Chen
  • Mingheng Liao
  • Lin Xu
  • Zhenru Wu
  • Kefei Yuan
  • Bin SongEmail author
  • Yong ZengEmail author
Hepatobiliary Tumors
  • 51 Downloads

Abstract

Background

To help identify potential hepatocellular carcinoma (HCC) candidates for immunotherapies, we aimed to develop and validate a radiomics-based biomarker (Rad score) to predict the infiltration of tumor-infiltrating CD8+ T cells in HCC patients, and to evaluate the correlation of Rad score with tumor immune characteristics.

Methods

Overall, 142 HCC patients (n = 100 and n = 42 in the training and validation sets, respectively) were subjected to radiomic feature extraction. Imaging features and immunochemistry data of patients in the training set were subjected to elastic-net regularized regression analysis to predict the level of CD8+ T cell infiltration.

Results

A Rad score for CD8+ T-cell infiltration, which contained seven variables, was developed and was validated in the validation set (area under the curve [AUC]: training set 0.751, 95% confidence interval [CI] 0.656–0.846; validation set 0.705, 95% CI 0.547–0.863). The decision curve indicated the clinical usefulness of the Rad score. A higher Rad score correlated with superior overall and disease-free survival outcomes (p = 0.012 and 0.0088, respectively). Using the pathological slides, we found that the Rad score positively correlated with the percentage of tumor-infiltrating lymphocytes (TILs; Spearman rho = 0.51, p < 0.0001). Moreover, the Rad score could also discriminate inflamed tumors from immune-desert and immune-excluded tumors (Kruskal–Wallis, p < 0.0001), and higher Rad scores could be found in patients with positive programmed cell death ligand 1 expression in tumor/immune cells, as well as those with positive programmed cell death protein 1 expression.

Conclusion

The newly developed Rad score was a powerful predictor of CD8+ T-cell infiltration, which could be useful in identifying potential HCC patients who can benefit from immunotherapies when validated in large-scale prospective cohorts.

Notes

Author Contributions

BS and YZ designed the whole project and participated in result evaluation. HL, ML, and ZZ collected the clinical data of HCC candidates. ZZ and JC participated in ROI segmentation and image feature extractions. LX and ZW participated in performing IHC and pathological analysis. HL and ZZ performed image feature selection and radiomic model construction. HL and ZZ conducted the data analysis and wrote the manuscript. KY modified the structure of manuscript. All authors reviewed the manuscript and approved the final version.

Funding

This work was supported by Grants from the Natural Science Foundation of China (81872004, 81800564, 81770615, 81700555, 81672882 and 81502441), the Science and Technology Support Program of Sichuan Province (2017SZ0003, 2018SZ0115), and the Science and Technology Program of Tibet Autonomous Region (XZ201801-GB-02).

Disclosures

Haotian Liao, Zhen Zhang, Jie Chen, Mingheng Liao, Lin Xu, Zhenru Wu, Kefei Yuan, Bin Song, and Yong Zeng declare no competing interests in this work.

Supplementary material

10434_2019_7815_MOESM1_ESM.docx (985 kb)
Supplementary material 1 (DOCX 985 kb)

References

  1. 1.
    Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefGoogle Scholar
  2. 2.
    Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, et al. A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg. 2016;263(6):1112–25.CrossRefGoogle Scholar
  3. 3.
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.CrossRefGoogle Scholar
  4. 4.
    Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.CrossRefGoogle Scholar
  5. 5.
    Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.CrossRefGoogle Scholar
  6. 6.
    Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, et al. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a series from Lysa centers. Am J Hematol. 2018.  https://doi.org/10.1002/ajh.25154.Google Scholar
  7. 7.
    Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81–8.CrossRefGoogle Scholar
  8. 8.
    El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502.CrossRefGoogle Scholar
  9. 9.
    Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–30.CrossRefGoogle Scholar
  10. 10.
    Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.CrossRefGoogle Scholar
  11. 11.
    Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35–44.CrossRefGoogle Scholar
  12. 12.
    Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27(8):1492–504.CrossRefGoogle Scholar
  13. 13.
    Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278(2):563–77.Google Scholar
  14. 14.
    Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441–6.CrossRefGoogle Scholar
  15. 15.
    Limkin EJ, Sun R, Dercle L, Zacharaki EI, Robert C, Reuze S, et al. Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology. Ann Oncol. 2017;28(6):1191–206.CrossRefGoogle Scholar
  16. 16.
    Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.CrossRefGoogle Scholar
  17. 17.
    Peng J, Zhang J, Zhang Q, Xu Y, Zhou J, Liu LJD, et al. A radiomics nomogram for preoperative prediction of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma. Diagn Interv Radiol. 2018;24(3):121–7.CrossRefGoogle Scholar
  18. 18.
    McAlinden C, Khadka J, Pesudovs K. Statistical methods for conducting agreement (comparison of clinical tests) and precision (repeatability or reproducibility) studies in optometry and ophthalmology. Ophthalmic Physiol Opt. 2011;31(4):330–8.CrossRefGoogle Scholar
  19. 19.
    Zwanenburg A, Leger S, Vallières M, Löck S. Image biomarker standardisation initiative—feature definitions. 2016.Google Scholar
  20. 20.
    Brunner SM, Rubner C, Kesselring R, Martin M, Griesshammer E, Ruemmele P, et al. Tumor-infiltrating, interleukin-33-producing effector-memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival. Hepatology. 2015;61(6):1957–67.CrossRefGoogle Scholar
  21. 21.
    Gabrielson A, Wu Y, Wang H, Jiang J, Kallakury B, Gatalica Z, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res. 2016;4(5):419–30.CrossRefGoogle Scholar
  22. 22.
    Sideras K, Biermann K, Verheij J, Takkenberg BR, Mancham S, Hansen BE, et al. PD-L1, Galectin-9 and CD8(+) tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. Oncoimmunology. 2017;6(2):e1273309.CrossRefGoogle Scholar
  23. 23.
    Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 1998;27(2):407–14.CrossRefGoogle Scholar
  24. 24.
    Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22(8):1865–74.CrossRefGoogle Scholar
  25. 25.
    Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev. 2015;41(10):868–76.CrossRefGoogle Scholar
  26. 26.
    Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–74.CrossRefGoogle Scholar
  27. 27.
    Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19(9):P1180–91.CrossRefGoogle Scholar
  28. 28.
    Pantic I, Pantic S, Paunovic J, Perovic M. Nuclear entropy, angular second moment, variance and texture correlation of thymus cortical and medullar lymphocytes: grey level co-occurrence matrix analysis. An Acad Bras Cienc. 2013;85(3):1063–72.CrossRefGoogle Scholar
  29. 29.
    Shamir L, Wolkow CA, Goldberg IG. Quantitative measurement of aging using image texture entropy. Bioinformatics. 2009;25(23):3060.CrossRefGoogle Scholar
  30. 30.
    Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50.CrossRefGoogle Scholar
  31. 31.
    Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012;72(5):1070–80.CrossRefGoogle Scholar
  32. 32.
    Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4.CrossRefGoogle Scholar
  33. 33.
    Sideras K, Biermann K, Yap K, Mancham S, Boor PPC, Hansen BE, et al. Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer. Int J Cancer. 2017;141(3):572–82.CrossRefGoogle Scholar
  34. 34.
    Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–13.CrossRefGoogle Scholar
  35. 35.
    Gajewski TF. The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment. Semin Oncol. 2015;42(4):663–71.CrossRefGoogle Scholar
  36. 36.
    Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71.CrossRefGoogle Scholar
  37. 37.
    Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.CrossRefGoogle Scholar
  38. 38.
    Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5(200):200ra116.CrossRefGoogle Scholar
  39. 39.
    Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, Costentin C, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology. 2016;64(6):2038–46.CrossRefGoogle Scholar
  40. 40.
    Liu CQ, Xu J, Zhou ZG, Jin LL, Yu XJ, Xiao G, et al. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. Br J Cancer. 2018;119(1):80–8.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Haotian Liao
    • 1
    • 4
  • Zhen Zhang
    • 2
  • Jie Chen
    • 2
  • Mingheng Liao
    • 1
    • 4
  • Lin Xu
    • 1
    • 4
  • Zhenru Wu
    • 3
  • Kefei Yuan
    • 1
    • 4
  • Bin Song
    • 2
    Email author
  • Yong Zeng
    • 1
    • 4
    Email author
  1. 1.Department of Liver Surgery, Liver Transplantation Division, West China HospitalSichuan UniversityChengduPeople’s Republic of China
  2. 2.Department of Radiology, West China HospitalSichuan UniversityChengduPeople’s Republic of China
  3. 3.Laboratory of Pathology, Department of Pathology, West China HospitalSichuan UniversityChengduPeople’s Republic of China
  4. 4.Laboratory of Liver Surgery, West China HospitalSichuan UniversityChengduPeople’s Republic of China

Personalised recommendations